Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

Novo Nordisk Partners with Neomorph to Target Undruggable Diseases with Molecular Glue Degraders

Fineline Cube Feb 27, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has entered into a partnership with US-based Neomorph...

Company

AstraZeneca Expands Global Footprint with Shanghai Strategic Center

Fineline Cube Feb 27, 2024

AstraZeneca (AZ, NASDAQ: AZN) has declared that Shanghai is now its fifth global strategic center,...

Company Deals

Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development

Fineline Cube Feb 26, 2024

Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co.,...

Company Deals Drug

Kelun-Biotech Launches Clinical Trials for SKB264, Triggering $75 Million Milestone Payment from MSD

Fineline Cube Feb 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) has announced the initiation of clinical trials for...

Company Drug

AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics

Fineline Cube Feb 26, 2024

AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA...

Company Deals

b-ONE Ortho Partners with THINK Surgical to Expand MOBIO Knee System in U.S. Market

Fineline Cube Feb 26, 2024

b-ONE Ortho Corp., a developer of artificial joint replacements with operations in the U.S. and...

Company Deals

CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System

Fineline Cube Feb 26, 2024

CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a...

Company Deals

Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal

Fineline Cube Feb 26, 2024

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation...

Policy / Regulatory

Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area

Fineline Cube Feb 26, 2024

The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch...

Company Deals Digital

Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations

Fineline Cube Feb 26, 2024

Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees...

Company Drug

Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension

Fineline Cube Feb 26, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...

Company Deals

Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries

Fineline Cube Feb 26, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...

Policy / Regulatory

Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits

Fineline Cube Feb 26, 2024

The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...

Company Drug

GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma

Fineline Cube Feb 26, 2024

GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...

Company Drug

Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC

Fineline Cube Feb 26, 2024

South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...

Company Drug

Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China

Fineline Cube Feb 26, 2024

The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...

Company Deals

Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Drug

Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development

Fineline Cube Feb 23, 2024

Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed...

Company Drug

Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio

Fineline Cube Feb 23, 2024

Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...

Posts pagination

1 … 335 336 337 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.